5 Texas companies present the future of health care at TMCx's Demo Day

Homegrown heroes

Over 700 people watched TMCx's Demo Day either in person or online. Photo by Cody Duty/TMC

After four months of product design, networking with medical professionals, pitching to investors, and more, 23 startup leaders had just a few minutes to show the medical community what they've achieved and where they're going next.

Over 700 attendees made it to TMCx's 7th Demo Day or tuned in online to see the results of Houston's award-winning medical devices accelerator program.

"It's really the draw of the experts within our 23 hospitals and clinics that really makes us quite special in our ecosystem compared to the East and West coasts," Texas Medical Center CEO Bill McKeon says. "We're proud to call ourselves the Third Coast of the life sciences."

The cohort, which is the most international to date with nine international companies, has already raised $73 million and confirmed 108 signed agreements for medical professional partnerships.

"The thing that cracks me up from time to time," says Erik Halvorsen, director of the TMC Innovation Institute, "is when you see these talks that say, 'what can the Houston ecosystem learn from Silicon Valley.' Well you know what, I think we're ready to flip that, and say, 'here's what can Silicon Valley learn from us here in Houston — what we've built and where we're headed.'"

From a wearable device that reduces back pain to a new technology that reduces suicidal thoughts, the cohort's presentations didn't disappoint. While all the cohorts made business connections to Houston in the months they were at TMCx, five of the 23 companies are based in Texas. Here are the companies with Lone Star State roots.

Articulate Labs

Articulate Labs' KneeStim allows for everyday activities to be muscle-building exercises.

Photo via articulatelabs.com

Herbie Kirn, co-founder and chief scientific officer of Articulate Labs, lost his leg from the knee down in a motorcycle accident and quickly wore through his other knee's cartilage. If he didn't do sufficient rehabilitation and physical therapy, he would lose function of that leg too.

Over 14 million people in the United States individuals suffer from chronic knee problems; however, whether it be due to time or cost, over 70 percent of those affected cannot attend the prescribed physical therapy.

Dallas-based Articulate Labs has a solution. The KneeStim device allows the patient to turn daily activities into rehabilitation exercises.

The company has raised a little over $500,000 already, but looks to raise $1 million with its next round of funding. Articulate Labs is also looking for more scientific and strategic partners.

Intelligent Implants

intelligent implants

Intelligent Implant's co-founder, Juan Pardo, told the crowd at Demo Day that his company's device allows for 50 percent faster bone growth in patients.

Photo by Cody Duty/TMC

Chronic lower back pain can result in a need for spinal fusion surgery — and 40 percent of those surgeries fail, says Juan Pardo, co-founder of Intelligent Implants, which has an office in Houston. Pardo and his team have come up with an implant that tracks post-op healing and introduces electronic stimulation wirelessly.

The device is the same size and shape as the spacer that surgeons currently use, but contains a technology that can deliver electronic stimulation therapy and monitor progress without needing batteries. The doctor is able to adjust treatment remotely, and the device can heal the patient 50 percent faster than the standard care.

Intelligent Implants was announced as the first in-residence company at the Center for Device Innovation by Johnson and Johnson and also launched its large animal studies. The company has a goal to raise $1.6 million, and has already secured $900,000 — $250,000 of which came from the new TMC Venture Fund.

Noleus Technologies

Swarna Balasubramaniam, an experienced surgeon, created a device that heal gastrointestinal surgery patients faster.

Photo by Cody Duty/TMC

Swarna Balasubramaniam watched helplessly as her mom slowly healed from gastrointestinal surgery. She couldn't eat and had trouble sleeping — both of which hindered her ability to heal quickly.

Balasubramaniam, founder of Houston-based Noleus Technologies, created a solution that reduces swelling in the bowels after operation. The disposable device is inserted into the abdomen at the time of surgery, and folds up like a fan to be removed without another surgery.

The invention is attractive to all parties involved. Patients are able to heal quicker, and surgeons are able to provide better care for their patients. Additionally, hospitals, which have bundled reimbursement for surgeries like this, are able to shorten the recovery time for patients thus reducing the costs spent on caring for the patient. Balasubramaniam says she estimates the device saving hospitals $4,000 per patient.

Vax-Immune Diagnostics

LabReady ensures samples make it from the patient to the lab without compromising the quality of the sample.

Photo via vaximmune.com

Over 70 percent of care decisions come from lab results, but more than 20 percent of microbiology lab tests are inaccurate due to problems in transport from the patient to the lab. Leonard Weisman, founder and chief technology officer of Houston-based Vax-Immune Diagnostics, invented Lab Ready — a tool for protecting the quality of the sample for testing.

The device is easy for patients to use at home and send to the lab directly, and the device is likewise easy to use by lab technicians.

Lab Ready is prepared to launch in 2019, immediately following FDA approval. Vax-Immune is on track to meet its funding goal of $5 million in the first quarter of 2019.

VenoStent

VenoStent wants every external stent procedure is successful on its first try.

Photo via venostent.com

Patients with kidney disease or diabetes have four chances to get an external stent successfully inserted into their arms for dialysis treatment, and the current standard of care results in a failure in half of these access sites, says Tim Biore, founder of Houston-based VenoStent.

It was Biore's vision to create a device that allows a successful stent implementation on the first try. VenoStent's SelfWrap is made from a shape-memory polymer that uses body heat to mold the stent into the vein-artery junction.

One in eight people suffer from kidney disease, and Biore says SelfWrap would save Medicare upwards of $200 million annually, while improving the success rate by 20 to 30 percent.

VenoStent has seven signed agreements from partners as a result of the accelerator program. The company is seeking $2.4 million to continue manufacturing as they await FDA clearance — expected in early 2022.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

3 Houston incubators and accelerators fueling the growth of local startups

Meet the finalists

It takes a village to launch a business. That's where Houston's network of incubators and accelerators can step in, providing the resources, mentorship and community needed to push a fledgling company forward.

As part of our 2026 Houston Innovation Awards, the Incubator/Accelerator of the Year category honors a local organization that is championing and fueling the growth of Houston startups.

Three incubators and accelerators have been named finalists for the 2026 award. They support startups ranging from hard-tech companies to food and youth concepts.

Read more about these organizations below. The 2026 winners will be announced on InnovationMap.com in mid-November.

Activate

Hard tech incubator Activate supports scientists in "the outset of their entrepreneurial journey." The Houston hub was introduced in 2024, and joins others in Boston, New York, and Berkley, California—where Activate is headquartered. It named its third Houston cohort this summer.

The two-year program graduated its first class of Houston fellows in 2026 and saw its first alumni IPO from Houston-based Fervo Energy, which previously participated in a Berkley cohort. Nationally, it has supported 346 fellows and 276 companies since 2015. Those companies have raised more than $6 billion in follow-on funding, according to Activate. In Houston, it has supported Houston startups like Solidec, FlowCellutions and Orbital Arc. Activate Houston is led by managing director Jeremy Pitts, who co-founded Greentown Labs in Boston. It is based out of the Ion.

Impact Hub Houston

Impact Hub Houston supports early-stage ventures at various stages of development through innovative programs that address pressing societal issues. The nonprofit organization supports social impact startups through mentorship, connections and training opportunities.

There are more than 110 Impact Hubs globally with members spanning 72 countries. Launched in 2018, Impact Hub Houston says its membership tripled by the beginning of 2026. This year brought major milestones for the community, including the launch of its Ideas to Impact Accelerator, which supported 11 founders across the health, education, food systems, civic technology and workforce development sectors. It also received funding from more than 20 international Impact Hubs to develop SYNC, a collaboration platform that 25 Impact Hubs across five continents have committed to pilot. The organization has worked with local startups including Myoviva Health, The Change Lab and INNERVERSE Inc.

MarMo Innovation

Galveston-based business incubator MarMo Innovation is focused on removing barriers to entrepreneurship. It aims to provide affordable space, education, mentorship, market access, connections and real-world opportunities that help entrepreneurs move from idea to launch to sustainable growth. The "industry-agnostic" incubator was founded in 2022 and is led by Executive Director Erica Delgadillo.

This year, the organization moved from primarily serving as a coworking and community space into a more comprehensive entrepreneurial incubator by expanding its MarMo Market, MarMo Market Jr. and Lunch LineUp programs. A major focus for MarMo is food entrepreneurship. It is developing an Incubator Kitchen, which MarMo says will support programs like its Cottage to Commercial Bootcamp and Food Biz 101. The organization also expanded its board this year and says it is diversifying its revenue through memberships, events, markets, equipment and space rentals, sponsorships, grants and new entrepreneurial programming.

Baylor College of Medicine launches VC fund to invest in biotech startups

fresh funding

Houston’s Baylor College of Medicine just unveiled a new venture capital fund that backs early-stage biotech startups—and it’s already made its first investment.

BCM Legacy Fund I, funded by philanthropies, invested an undisclosed amount in Houston biotech startup Nemea Therapeutics. Nemea, a spinout of the Baylor College of Medicine and Germany’s Lead Discovery Center, is developing an oral drug to treat metastatic triple-negative breast cancer that no longer responds to currently available therapies.

This type of aggressive cancer spreads from the breast to other areas of the body, such as the bones, liver, lungs or brain. Roughly 38,000 to 57,000 Americans are diagnosed each year with metastatic triple-negative breast cancer. One study showed about half of patients survive past the one-year mark following diagnosis and about one-third survive two years.

“Baylor College of Medicine’s laboratories produce discoveries with the potential to change patients’ lives, and too many of them stall where academic funding ends and private investment has not yet begun,” Dr. Jakub Tolar, president, CEO and executive dean of the Baylor College of Medicine, said in a press release. “The BCM Legacy Fund fills that gap, giving our scientists a path to advance their discoveries to patients.”

The National Institutes of Health awards more than $36 billion per year for biomedical research in the U.S., Baylor said. But some biomedical discoveries “never leave the starting line because they don’t yet fit the economics of venture capital,” the college said.

“The forefront of a new model”

The BCM Legacy Fund aggregates philanthropic capital from private foundations and donor-advised funds. It then invests in startups so they can move beyond that starting line and into later-stage investment rounds. The Greater Houston Community Foundation is the fund’s philanthropic partner.

“It’s exciting to be on the forefront of a new model for philanthropic capital,” said Houston entrepreneur and investor Burton Hanson, managing partner of the fund.

“Not only do we hope to solve a real problem by advancing these therapies to the patients who need them most, but we also hope this model will inspire others in the city and beyond toward philanthropic creativity and a posture of ‘I sacrifice; we win.’”

The fund expects to invest in about 15 early-stage startups over a five-year span. Baylor declined to divulge the amount of money in the fund and the size of the investment in Nemea.

Nemea’s “world-class chemistry”

Hanson oversees the Baylor fund alongside Chicago investor Steve Lehmann, who led the University of Chicago’s Innovation Fund.

Lehmann said Nemea, the fund’s first portfolio company, “has world-class chemistry, Baylor biology, and patients with no good options. Our job is to fund the experiments that carry it to the next handoff, so that industry and later-stage investors can take it from there.”

Based at Houston’s massive Texas Medical Center, Nemea plans to start clinical trials next year in collaboration with Baylor’s Lester and Sue Smith Breast Center.

Nemea previously received $9 million from the Lead Discovery Center and a $1.6 million grant from Baylor. Last year, the startup said it was seeking $25 million to $30 million in seed and Series A funding.

Debra McCoy of Houston, a former managing director at BlackRock and former partner at Bain & Co., and Paul Thomas, co-founder and CEO of Spring-based benefits manager Luscinia Health, sit on the Baylor fund’s governing board. Dr. Paul Klotman, former president, CEO and executive dean of Baylor, is a senior strategic adviser.

How does the fund find investment targets?

The Baylor Legacy Fund relies on two tools to help unearth early-stage biotech startups:

  • High-resolution “innovation maps” of research institutions. These maps surface hidden clusters of innovation, identify rising-star researchers and tie pockets of “innovation supply” at Baylor to areas of “innovation demand” in biotech.
  • AI-enhanced due diligence. AI agents assist with due diligence of early-stage biotech startups. The fund says the platform “distills the frameworks we’ve developed over a decade of teaching and investing into a flexible … diligence environment.”

MD Anderson unveils $3.4B expansion with two new Houston cancer care facilities

major expansion

The cutting edge of cancer-fighting technology and science is getting even sharper after MD Anderson announced last week that it will open two new facilities in the Texas Medical Center within the next five years. Inspiration Tower and Prism will expand MD Anderson’s annual patient load in the TMC to 250,000 annually and will incorporate a variety of new techniques.

The $3.4 billion project will add 2 million square feet to MD Anderson's TMC footprint, bringing its total campus size to 22 million square feet by 2032. Located at the corner of Fannin Street and Holcombe Boulevard, the cancer center says the two new facilities will serve as its new "front door" to the TMC.

“Every detail of these buildings, from the technology to the treatment rooms, was designed around our patients who will receive their care in them and our employees who will work in them. The facilities will serve as a physical representation of hope for the patients and their families who will walk through the doors,” Dr. Jeffrey E. Lee, president ad interim of UT MD Anderson, said in a news release. “Inspiration Tower and Prism are the future of cancer care, and we are grateful for the longstanding support and guidance we’ve received from the UT System Board of Regents to bring these projects to life. These facilities are part of the most impactful capital expansion in UT MD Anderson’s history.”

Prism is especially exciting as it will represent fully half of the linear accelerator treatment in the TMC. Linear accelerator is a radiation treatment that uses magnetically charged fields to deliver targeted external radiation therapy, like shooting cancer with a rail gun. The treatment is safer and has fewer side effects than older radiation treatments.

In addition, Prism will contain 12 MRI machines, four CT scanners, two PET-CT units, 18 radiation vaults and seven radiation simulators. Patient comfort has also been put at a premium with multiple gardens and roof overlooks.

“Every patient we treat deserves an environment that reflects the excellence of the care they receive at UT MD Anderson,” Chris McKee, executive vice president and chief strategy officer at UT MD Anderson, added in the release. “Our new facilities will be innovative, agile, adaptable and beautiful, and they will allow us to care for more patients, more effectively – in an environment that enhances healing and well-being. We are building for our future and for every patient who will be counting on us.”

Prism is slated to open in 2030.

Inspiration Tower will have 25 floors of surgical, diagnostic, and treatment services. At 1.4 million square feet, it’s currently expected to be the largest cancer-specific treatment facility in the United States. The tower will be divided into units for specific types of cancer, making it easy to integrate the advancing research being done all over Houston.

Like Prism, Inspiration Tower is specifically designed to offer comfort and reassurance, with more garden space, terraces, and beautiful scenery to ease patient distress. It is expected to open in 2032.

View All Listings